©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Dec 10, 2015; 6(6): 252-263
Published online Dec 10, 2015. doi: 10.5306/wjco.v6.i6.252
Published online Dec 10, 2015. doi: 10.5306/wjco.v6.i6.252
Biomarkers in triple negative breast cancer: A review
Budhi S Yadav, Department of Radiotherapy, PGIMER, Chandigarh 160012, India
Priyanka Chanana, Department of Pharmacology, Panjab University, Chandigarh 160012, India
Swaty Jhamb, Dr HS Judge Institute of Dental Sciences, Panjab University, Chandigarh 160012, India
Author contributions: Yadav BS designed and wrote manuscript; Chanana P gathered published studies; Jhamb S reviewed and edited the manuscript.
Conflict-of-interest statement: None.
Correspondence to: Dr. Budhi S Yadav, Associate Professor, Department of Radiotherapy, PGIMER, Sector 12, Chandigarh 160012, India. drbudhi@gmail.com
Telephone: +91-172-2756390 Fax: +91-172-2744401
Received: May 8, 2014
Peer-review started: May 9, 2014
First decision: July 11, 2014
Revised: September 3, 2015
Accepted: October 1, 2015
Article in press: October 8, 2015
Published online: December 10, 2015
Processing time: 580 Days and 8.5 Hours
Peer-review started: May 9, 2014
First decision: July 11, 2014
Revised: September 3, 2015
Accepted: October 1, 2015
Article in press: October 8, 2015
Published online: December 10, 2015
Processing time: 580 Days and 8.5 Hours
Core Tip
Core tip: Triple negative breast cancer (TNBC) are type of breast cancer which lack of estrogen receptors, progesterone receptors and human epidermal growth factor receptor. It is a complex disease subtype with many subclasses. There are many biomarkers in TNBC used for its sub-classification. Clinically-practical assay/biomarkers that can reliably identify TNBC are necessary. Biomarkers may be useful as prognostic or predictive indicators as well as suggest possible targets for novel therapies.